Bicycle Therapeutics to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference
Bicycle Therapeutics (NASDAQ: BCYC), a pharmaceutical company specializing in bicyclic peptide technology, has announced its participation in the Oppenheimer 35th Annual Healthcare Life Sciences Conference. The company's management will engage in a fireside chat on Wednesday, February 12, at 10 a.m. ET.
The event will be accessible through a live webcast available on the Investor section of Bicycle Therapeutics' website (www.bicycletherapeutics.com). For those unable to attend live, a replay of the webcast will be archived and made available after the event.
Bicycle Therapeutics (NASDAQ: BCYC), una compagnia farmaceutica specializzata nella tecnologia dei peptidi ciclici, ha annunciato la sua partecipazione alla 35ª Conferenza Annuale sulle Life Sciences di Oppenheimer. Il management dell'azienda parteciperà a una chiacchierata informale mercoledì 12 febbraio, alle 10:00 ET.
L'evento sarà accessibile tramite un webcast in diretta disponibile nella sezione Investor del sito web di Bicycle Therapeutics (www.bicycletherapeutics.com). Per coloro che non possono partecipare in diretta, una registrazione del webcast sarà archiviata e resa disponibile dopo l'evento.
Bicycle Therapeutics (NASDAQ: BCYC), una empresa farmacéutica especializada en tecnología de péptidos bicíclicos, ha anunciado su participación en la 35ª Conferencia Anual de Ciencias de la Salud de Oppenheimer. La dirección de la empresa estará involucrada en una charla informal el miércoles 12 de febrero a las 10 a.m. ET.
El evento será accesible a través de un webcast en vivo disponible en la sección de Inversores del sitio web de Bicycle Therapeutics (www.bicycletherapeutics.com). Para aquellos que no puedan asistir en vivo, se archivará una repetición del webcast y estará disponible después del evento.
바이시클 테라퓨틱스 (NASDAQ: BCYC)는 이중 고리 펩타이드 기술 전문 제약 회사로서 오펜하이머 제35회 연례 헬스케어 생명과학 컨퍼런스에 참여한다고 발표했습니다. 회사 경영진은 2월 12일 수요일 오전 10시(ET)에 파이어사이드 챗에 참여할 예정입니다.
이번 행사는 바이시클 테라퓨틱스 웹사이트(www.bicycletherapeutics.com)의 투자자 섹션을 통해 실시간 웹캐스트로 접근할 수 있습니다. 실시간 참석이 불가능한 경우, 웹캐스트의 재생이 저장되어 이벤트 종료 후에 제공될 것입니다.
Bicycle Therapeutics (NASDAQ: BCYC), une entreprise pharmaceutique spécialisée dans la technologie des peptides bicycliques, a annoncé sa participation à la 35e Conférence Annuelle sur les Sciences de la Vie d'Oppenheimer. La direction de l'entreprise participera à une discussion informelle mercredi 12 février à 10h00 ET.
L'événement sera accessible via un webinaire en direct disponible dans la section Investisseurs du site Web de Bicycle Therapeutics (www.bicycletherapeutics.com). Pour ceux qui ne peuvent pas assister en direct, une rediffusion du webinaire sera archivée et mise à disposition après l'événement.
Bicycle Therapeutics (NASDAQ: BCYC), ein Pharmaunternehmen, das sich auf zyklische Peptidtechnologie spezialisiert hat, hat seine Teilnahme an der 35. jährlichen Healthcare Life Sciences-Konferenz von Oppenheimer angekündigt. Das Management des Unternehmens wird am Mittwoch, den 12. Februar, um 10 Uhr ET an einem Fireside-Chat teilnehmen.
Die Veranstaltung wird über ein Live-Webcast zugänglich sein, das im Investorenbereich der Website von Bicycle Therapeutics (www.bicycletherapeutics.com) verfügbar ist. Für diejenigen, die nicht live teilnehmen können, wird eine Aufzeichnung des Webcasts archiviert und nach der Veranstaltung verfügbar gemacht.
- None.
- None.
A live webcast of the fireside chat will be accessible from the Investor section of the company’s website at www.bicycletherapeutics.com. A replay of the webcast will be archived and available following the event.
About Bicycle Therapeutics
Bicycle Therapeutics is a clinical-stage pharmaceutical company developing a novel class of medicines, referred to as Bicycle® molecules, for diseases that are underserved by existing therapeutics. Bicycle molecules are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. This constraint facilitates target binding with high affinity and selectivity, making Bicycle molecules attractive candidates for drug development. The company is evaluating zelenectide pevedotin (formerly BT8009), a Bicycle® Toxin Conjugate (BTC®) targeting Nectin-4, a well-validated tumor antigen; BT5528, a BTC molecule targeting EphA2, a historically undruggable target; and BT7480, a Bicycle Tumor-Targeted Immune Cell Agonist® (Bicycle TICA®) targeting Nectin-4 and agonizing CD137, in company-sponsored clinical trials. Additionally, the company is developing Bicycle® Radionuclide Conjugates (BRC®) for radiopharmaceutical use and, through various partnerships, is exploring the use of Bicycle® technology to develop therapies for diseases beyond oncology.
Bicycle Therapeutics is headquartered in
View source version on businesswire.com: https://www.businesswire.com/news/home/20250205759104/en/
Investors:
Stephanie Yao
SVP, Investor Relations and Corporate Communications
ir@bicycletx.com
857-523-8544
Matthew DeYoung
Argot Partners
ir@bicycletx.com
212-600-1902
Media:
Jim O’Connell
Weber Shandwick
media@bicycletx.com
312-988-2343
Source: Bicycle Therapeutics plc
FAQ
When is Bicycle Therapeutics (BCYC) presenting at the Oppenheimer Healthcare Conference?
How can investors watch Bicycle Therapeutics' (BCYC) Oppenheimer Conference presentation?
What type of presentation will BCYC give at the Oppenheimer Healthcare Conference?
Will there be a replay available of BCYC's Oppenheimer Conference presentation?
